SMILES string
[Na+].[Na+].[P](=O)([O-])(O)C([P](=O)([O-])O)(O)C
InChI
1S/C2H8O7P2.2Na/c1-2(3,10(4,5)6)11(7,8)9;;/h3H,1H3,(H2,4,5,6)(H2,7,8,9);;/q;2*+1/p-2
InChI key
GWBBVOVXJZATQQ-UHFFFAOYSA-L
grade
pharmaceutical primary standard
API family
etidronate
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Etidronate disodium EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
pcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Determination of etidronate disodium tablets by ion chromatography with indirect UV detection.
Tsai E W, et al.
Journal of Pharmaceutical and Biomedical Analysis, 11(6), 513-516 (1993)
S M Krane
Annals of internal medicine, 96(5), 619-625 (1982-05-01)
Control of Paget's disease of bone has been possible through treatment with agents that decrease bone resorption; calcitonins, diphosphonates, and mithramycin. The pagetic lesion is not, however, cured. Etidronate disodium is one of the diphosphonates. The clinical improvement attained with
The role of risedronate in osteopenia in Crohn's disease.
Alice Buchan et al.
Gut, 64(1), 185-185 (2013-12-07)
Ivana Sestak et al.
The Lancet. Oncology, 15(13), 1460-1468 (2014-12-03)
Aromatase inhibitors prevent breast cancer in postmenopausal women at high risk of the disease but are associated with accelerated bone loss. We assessed effectiveness of oral risedronate for prevention of reduction in bone mineral density (BMD) after 3 years of
Jörg Schilcher et al.
Acta orthopaedica, 86(1), 100-107 (2015-01-15)
Use of bisphosphonates in women is associated with higher risk of atypical femoral fractures. The risk in terms of timing of use and type of bisphosphonate, and in men, remains unclear. We reviewed radiographs of 5,342 Swedish women and men
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持